Published in Chemother Res Pract on November 07, 2012
Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors | NCT00730470
Targeting of erbB3 receptor to overcome resistance in cancer treatment. Mol Cancer (2014) 1.22
Combination of anti-HER3 antibody MM-121/SAR256212 and cetuximab inhibits tumor growth in preclinical models of head and neck squamous cell carcinoma. Mol Cancer Ther (2014) 1.05
Examination of HER3 targeting in cancer using monoclonal antibodies. Proc Natl Acad Sci U S A (2015) 0.88
HER3 protein expression in relation to HER2 positivity in patients with primary colorectal cancer: clinical relevance and prognostic value. Virchows Arch (2015) 0.80
Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers. Mol Diagn Ther (2014) 0.80
A computational strategy to select optimized protein targets for drug development toward the control of cancer diseases. PLoS One (2015) 0.79
Model-based analysis of HER activation in cells co-expressing EGFR, HER2 and HER3. PLoS Comput Biol (2013) 0.78
HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells. Oncoimmunology (2014) 0.76
Recent developments in receptor tyrosine kinases targeted anticancer therapy. Vet World (2016) 0.76
Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1. Oncotarget (2016) 0.75
ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1). PLoS One (2017) 0.75
Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells. Mol Pharm (2017) 0.75
Human Epidermal Growth Factor Receptor-3 mRNA Expression as a Prognostic Marker for Invasive Duct Carcinoma not Otherwise Specified. J Clin Diagn Res (2017) 0.75
Assessing Gonadotropin Receptor Function by Resonance Energy Transfer-Based Assays. Front Endocrinol (Lausanne) (2015) 0.75
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
Untangling the ErbB signalling network. Nat Rev Mol Cell Biol (2001) 28.05
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature (1984) 17.70
ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer (2005) 16.73
Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature (1984) 14.21
Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med (2008) 11.86
The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J (2000) 9.51
Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (1985) 9.12
Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res (2005) 7.66
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature (2007) 6.56
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A (2003) 6.37
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer (2009) 6.28
A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature (2005) 5.75
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol (2003) 5.22
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med (2011) 4.51
ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol (1994) 4.49
Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res (2008) 4.30
Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci U S A (1989) 4.17
Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene (1995) 4.10
The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem (1997) 4.03
A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res (2008) 3.93
Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol Syst Biol (2005) 3.48
Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J (1994) 3.42
Specificity within the EGF family/ErbB receptor family signaling network. Bioessays (1998) 3.37
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene (2003) 3.32
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res (2006) 3.28
Molecular cloning and expression of an additional epidermal growth factor receptor-related gene. Proc Natl Acad Sci U S A (1990) 3.11
Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J (1995) 2.87
ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci U S A (2010) 2.85
Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal (2009) 2.57
Insulin-like growth factor II precursor gene organization in relation to insulin gene family. Nature (1984) 2.53
Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer. Clin Cancer Res (2011) 2.45
Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol (2011) 2.36
Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. Clin Cancer Res (2003) 2.33
Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res (2006) 2.21
Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer (2007) 2.20
An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res (2010) 2.14
Expression of the ERBB3 gene product in breast cancer. Br J Cancer (1992) 2.01
Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. Cancer Res (2009) 1.98
Human chromosomal mapping of genes for insulin-like growth factors I and II and epidermal growth factor. Nature (1984) 1.97
Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Cancer Cell (2011) 1.92
Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein. Biochem J (1997) 1.91
The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther (2008) 1.90
Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer (1998) 1.88
Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J Biol Chem (1996) 1.87
Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res (2006) 1.85
ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface. FEBS Lett (2004) 1.79
Chicken epidermal growth factor (EGF) receptor: cDNA cloning, expression in mouse cells, and differential binding of EGF and transforming growth factor alpha. Mol Cell Biol (1988) 1.77
ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase. Biochem J (1998) 1.71
Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res (1999) 1.60
Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein. Biochem J (1998) 1.57
Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther (2012) 1.53
Differential expression of epidermal growth factor-related proteins in human colorectal tumors. Proc Natl Acad Sci U S A (1991) 1.52
Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res (2005) 1.49
C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer (1996) 1.44
ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib. Cancer Biol Ther (2007) 1.43
ErbBs in mammary development. Exp Cell Res (2003) 1.38
Expression and nuclear localization of ErbB3 in prostate cancer. Clin Cancer Res (2006) 1.36
The influence of heregulins on human Schwann cell proliferation. J Neurosci (1995) 1.34
HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res (2008) 1.33
Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol (1998) 1.30
Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors. Lancet Oncol (2009) 1.27
Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line. Curr Oncol (2012) 1.27
c-erbB-3 protein expression in human breast cancer: comparison with other tumour variables and survival. Histopathology (1994) 1.21
Analysis of Grb7 recruitment by heregulin-activated erbB receptors reveals a novel target selectivity for erbB3. J Biol Chem (1998) 1.21
Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer (2002) 1.20
Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene (1989) 1.20
HER3 and mutant EGFR meet MET. Nat Med (2007) 1.19
Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers. Mol Biol Cell (2002) 1.14
HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation. Cancer Res (2010) 1.13
The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer. Discov Med (2011) 1.12
Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549. Oncogene (2005) 1.08
Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation. Breast Cancer Res Treat (2006) 1.08
Recent advances in novel targeted therapies for HER2-positive breast cancer. Anticancer Drugs (2012) 1.06
ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma. Cancer Biol Ther (2010) 1.06
Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer (2006) 1.04
Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma. J Transl Med (2011) 1.04
Regulation of multiple tumor microenvironment markers by overexpression of single or paired combinations of ErbB receptors. Cancer Res (2003) 0.99
Changes in ErbB2 (her-2/neu), ErbB3, and ErbB4 during growth, differentiation, and apoptosis of normal rat mammary epithelial cells. J Histochem Cytochem (2000) 0.99
Resistance to EGFR-targeted therapy: a family affair. Cancer Cell (2011) 0.97
Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block. Immunol Endocr Metab Agents Med Chem (2011) 0.97
Current status of targeted therapies in advanced gastric cancer. Expert Opin Ther Targets (2012) 0.94
Targeting ErbB3-mediated stromal-epithelial interactions in pancreatic ductal adenocarcinoma. Br J Cancer (2011) 0.93
ERBB3 kinase domain mutations are rare in lung, breast and colon carcinomas. Int J Cancer (2006) 0.92
Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRAS. Curr Oncol (2012) 0.90
Expression of c-erbB proto-oncogene family members in squamous cell carcinoma of the head and neck. Anticancer Res (1998) 0.89
Mutation of a Shc binding site tyrosine residue in ErbB3/HER3 blocks heregulin-dependent activation of mitogen-activated protein kinase. J Biol Chem (1998) 0.89
HER-3 in colorectal tumourigenesis: from mRNA levels through protein status to clinicopathologic relationships. Eur J Cancer (2007) 0.87
Neuronal survival: early dependence on Schwann cells. Curr Biol (1998) 0.86
Prognostic significance of ERBB3 overexpression in oral squamous cell carcinoma. Cancer Lett (1995) 0.85
Nuclear HER3 is associated with favorable overall survival in uveal melanoma. Int J Cancer (2011) 0.82
Overexpression of c-erbB-3 in various stages of human squamous cell carcinomas. Oncology (1998) 0.82
Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov (2008) 12.72
Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res (2008) 5.67
Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res (2005) 2.43
Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int J Nanomedicine (2008) 2.20
Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin (2008) 2.15
Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. Cancer Prev Res (Phila) (2013) 1.56
p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells. J Clin Invest (2010) 1.50
CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models. Cancer Res (2007) 1.38
Detection of circulating tumor cells in human peripheral blood using surface-enhanced Raman scattering nanoparticles. Cancer Res (2011) 1.36
Adenoid cystic carcinoma of the head and neck: Incidence and survival trends based on 1973-2007 Surveillance, Epidemiology, and End Results data. Cancer (2012) 1.33
HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. ACS Nano (2009) 1.29
HPV positive squamous cell carcinoma of the oropharynx. Are we observing an unusual pattern of metastases? Head Neck Pathol (2012) 1.21
Understanding metastatic SCCHN cells from unique genotypes to phenotypes with the aid of an animal model and DNA microarray analysis. Clin Exp Metastasis (2006) 1.19
Chemokine receptor 7 activates phosphoinositide-3 kinase-mediated invasive and prosurvival pathways in head and neck cancer cells independent of EGFR. Oncogene (2005) 1.13
Detection of Cancer Metastasis Using a Novel Macroscopic Hyperspectral Method. Proc SPIE Int Soc Opt Eng (2012) 1.11
Enhanced anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin: potential role of p53. J Biol Chem (2010) 1.08
New perspectives of curcumin in cancer prevention. Cancer Prev Res (Phila) (2013) 1.05
Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. Clin Cancer Res (2013) 1.02
Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer. Cancer Biol Ther (2012) 1.02
Advances of cancer therapy by nanotechnology. Cancer Res Treat (2009) 1.01
Paranasal sinus squamous cell carcinoma incidence and survival based on Surveillance, Epidemiology, and End Results data, 1973 to 2009. Cancer (2013) 1.00
Quantum dot-based quantification revealed differences in subcellular localization of EGFR and E-cadherin between EGFR-TKI sensitive and insensitive cancer cells. Nanotechnology (2009) 0.99
Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth. J Control Release (2012) 0.99
Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther (2005) 0.97
A Minimum Spanning Forest-Based Method for Noninvasive Cancer Detection With Hyperspectral Imaging. IEEE Trans Biomed Eng (2015) 0.95
Targeted delivery of cisplatin to lung cancer using ScFvEGFR-heparin-cisplatin nanoparticles. ACS Nano (2011) 0.95
RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy. Clin Cancer Res (2013) 0.95
Prognostic impact of Fas-associated death domain, a key component in death receptor signaling, is dependent on the presence of lymph node metastasis in head and neck squamous cell carcinoma. Cancer Biol Ther (2013) 0.95
A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model. ACS Nano (2011) 0.94
Correlation of protease-activated receptor-1 with differentiation markers in squamous cell carcinoma of the head and neck and its implication in lymph node metastasis. Clin Cancer Res (2004) 0.93
Real-world effectiveness of systemic agents approved for advanced non-small cell lung cancer: a SEER-Medicare analysis. Oncologist (2013) 0.91
Comparison of quantum dot technology with conventional immunohistochemistry in examining aldehyde dehydrogenase 1A1 as a potential biomarker for lymph node metastasis of head and neck cancer. Eur J Cancer (2012) 0.91
Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma. Cancer Prev Res (Phila) (2009) 0.90
Tumor cytotoxicity of 5,6-dimethyl-1,10-phenanthroline and its corresponding gold(III) complex. J Inorg Biochem (2011) 0.90
Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and epigallocatechin-3-gallate: the role of p53-dependent inhibition of nuclear factor-kappaB. Cancer Prev Res (Phila) (2009) 0.90
Targeted iron-oxide nanoparticle for photodynamic therapy and imaging of head and neck cancer. ACS Nano (2014) 0.89
Localization-specific LKB1 loss in head and neck squamous cell carcinoma metastasis. Head Neck (2010) 0.87
A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment. Int J Cancer (2011) 0.87
Down-regulation of S100A2 in lymph node metastases of head and neck cancer. Head Neck (2007) 0.86
Atypical carcinoid tumor of the lung: a surveillance, epidemiology, and end results database analysis. J Thorac Oncol (2015) 0.85
Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer. J Thorac Oncol (2013) 0.85
Biodistribution Study of Nanoparticle Encapsulated Photodynamic Therapy Drugs Using Multispectral Imaging. Proc SPIE Int Soc Opt Eng (2013) 0.82
Oral Cavity Cancer: Risk Factors, Pathology, and Management. Oncology (2015) 0.82
Quantum dot-based, quantitative, and multiplexed assay for tissue staining. ACS Appl Mater Interfaces (2013) 0.81
Interruption of nuclear localization of ATBF1 during the histopathologic progression of head and neck squamous cell carcinoma. Head Neck (2012) 0.81
Sequence dependence of cell growth inhibition by EGFR-tyrosine kinase inhibitor ZD1839, docetaxel, and cisplatin in head and neck cancer. Head Neck (2009) 0.80
Do 18F-FDG PET/CT parameters in oropharyngeal and oral cavity squamous cell carcinomas indicate HPV status? Clin Nucl Med (2015) 0.80
Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic Review. J Thorac Oncol (2015) 0.79
Human papillomavirus 16 oncoprotein regulates the translocation of β-catenin via the activation of epidermal growth factor receptor. Cancer (2014) 0.79
Mutation and Transcriptional Profiling of Formalin-Fixed Paraffin Embedded Specimens as Companion Methods to Immunohistochemistry for Determining Therapeutic Targets in Oropharyngeal Squamous Cell Carcinoma (OPSCC): A Pilot of Proof of Principle. Head Neck Pathol (2014) 0.78
Esophagogastric junction and gastric adenocarcinoma: current challenges and future directions. Oncology (Williston Park) (2014) 0.78
Heat shock protein 90 (HSP90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of chemoradiation. Cancer Chemother Pharmacol (2014) 0.78
Induction of cell cycle arrest and apoptosis by a combined treatment with 13-cis-retinoic acid, interferon-alpha2a, and alpha-tocopherol in squamous cell carcinoma of the head and neck. Head Neck (2007) 0.77
Combination of erlotinib and EGCG induces apoptosis of head and neck cancers through posttranscriptional regulation of Bim and Bcl-2. Apoptosis (2015) 0.76
Clinical efficacy of targeted biologic agents as second-line therapy of advanced thyroid cancer. Oncologist (2013) 0.76
Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells. J Recept Signal Transduct Res (2009) 0.76
Antitumor properties of five-coordinate gold(III) complexes bearing substituted polypyridyl ligands. J Inorg Biochem (2013) 0.76
Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice. Cancer Chemother Pharmacol (2011) 0.76
Current treatment of T1N0 squamous cell carcinoma of the glottic larynx. Eur Arch Otorhinolaryngol (2014) 0.75
Adenosquamous Carcinoma of the Esophagus: An NCDB-Based Investigation on Comparative Features and Overall Survival in a Rare Tumor. Oncology (2017) 0.75
PASuite: a preprocessing algorithm suite for cellular and molecular image classification in cancer diagnosis and treatment. Conf Proc IEEE Eng Med Biol Soc (2008) 0.75